About: Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.22 (+0.48%)
ARTV NASDAQ Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc. Common Stock share price
Atividade de preço de ARTV
Último preço
$ 4,220
Variação (24h)
0,02 USD (0,48%)
Volume
753.92K
Volume (média 4 sem.)
-
Abertura
$ 4,25
Variação do dia
$ 4,16 - $ 4,27
Fechamento anterior
$ 4,20
Último negócio
04 Nov, 9:00 pm GMT+0
Atrasado
04 Nov, 9:00 pm GMT+0
ARTV price performance
Atrasado
04 Nov, 9:00 pm GMT+0
ARTV details
quote.marketSignals